Inhibition of fumarate reductase in Leishmania major and L-donovani by chalcones

被引:176
作者
Chen, M
Zhai, L
Christensen, SB
Theander, TG
Kharazmi, A
机构
[1] Univ Copenhagen Hosp, Ctr Med Parasitol, Dept Clin Microbiol, Copenhagen, Denmark
[2] Royal Danish Sch Pharm, Dept Med Chem, Copenhagen, Denmark
[3] Statens Serum Inst, DK-2300 Copenhagen, Denmark
[4] Univ Copenhagen, Inst Med Microbiol & Immunol, Copenhagen, Denmark
关键词
D O I
10.1128/AAC.45.7.2023-2029.2001
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Our previous studies have shown that chalcones exhibit potent antileishmanial and antimalarial activities in vitro and in vivo. Preliminary studies showed that these compounds destroyed the ultrastructure of Leishmania parasite mitochondria and inhibited the respiration and the activity of mitochondrial dehydrogenases of Leishmania parasites. The present study was designed to further investigate the mechanism of action of chalcones, focusing on the parasite respiratory chain. The data show that licochalcone A inhibited the activity of fumarate reductase (FRD) in the permeabilized Leishmania major promastigote and in the parasite mitochondria, and it also inhibited solubilized FRD and a purified FRD from L. donovani. Two other chalcones, 2,4-dimethoxy-4'-allyloxychalcone (24m4ac) and 2,4-dimethoxy-4'-butoxychalcone (24mbc), also exhibited inhibitory effects on the activity of solubilized FRD in L. major promastigotes. Although licochalcone A inhibited the activities of succinate dehydrogenase (SDH), NADH dehydrogenase (NDH), and succinate and NADH-cytochrome c reductases in the parasite mitochondria, the 50% inhibitory concentrations (IC50) of licochalcone A for these enzymes were at least 20 times higher than that for FRD, The IC50 of licochalcone A for SDH and NDH in human peripheral blood mononuclear cells were at least 70 times higher than that for FRD. These findings indicate that FRD, one of the enzymes of the parasite respiratory chain, might be the specific target for the chalcones tested. Since FRD exists in the Leishmania parasite and does not exist in mammalian cells, it could be an excellent target for antiprotozoal drugs.
引用
收藏
页码:2023 / 2029
页数:7
相关论文
共 40 条
[11]  
Christmas PB, 2000, FEMS MICROBIOL LETT, V183, P225, DOI 10.1111/j.1574-6968.2000.tb08962.x
[12]   SUCCINATE-DEPENDENT METABOLISM IN TRYPANOSOMA-CRUZI EPIMASTIGOTES [J].
DENICOLASEOANE, A ;
RUBBO, H ;
PRODANOV, E ;
TURRENS, JF .
MOLECULAR AND BIOCHEMICAL PARASITOLOGY, 1992, 54 (01) :43-50
[13]   Disruption of the trypanothione reductase gene of Leishmania decreases its ability to survive oxidative stress in macrophages [J].
Dumas, C ;
Ouellette, M ;
Tovar, J ;
Cunningham, ML ;
Fairlamb, AH ;
Tamar, S ;
Olivier, M ;
Papadopoulou, B .
EMBO JOURNAL, 1997, 16 (10) :2590-2598
[14]   MITOCHONDRIA OF MAMMALIAN PLASMODIUM SPP [J].
FRY, M ;
BEESLEY, JE .
PARASITOLOGY, 1991, 102 :17-26
[15]   Structure-activity relationships for the antileishmanial and antitrypanosomal activities of 1'-substituted 9-anilinoacridines [J].
Gamage, SA ;
Figgitt, DP ;
Wojcik, SJ ;
Ralph, RK ;
Ransijn, A ;
Mauel, J ;
Yardley, V ;
Snowdon, D ;
Croft, SL ;
Denny, WA .
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (16) :2634-2642
[16]   Fumarate reductase is essential for Helicobacter pylori colonization of the mouse stomach [J].
Ge, ZM ;
Feng, Y ;
Dangler, CA ;
Xu, SL ;
Taylor, NS ;
Fox, JG .
MICROBIAL PATHOGENESIS, 2000, 29 (05) :279-287
[17]   ESR STUDIES ON IRON-SULFUR CLUSTERS OF COMPLEX-II IN ASCARIS-SUUM MITOCHONDRIA WHICH EXHIBITS STRONG FUMARATE REDUCTASE-ACTIVITY [J].
HATATANAKA, A ;
KITA, K ;
FURUSHIMA, R ;
OYA, H ;
ITOH, S .
FEBS LETTERS, 1988, 242 (01) :183-186
[18]   Structure of the Escherichia coli fumarate reductase respiratory complex [J].
Iverson, TM ;
Luna-Chavez, C ;
Cecchini, G ;
Rees, DC .
SCIENCE, 1999, 284 (5422) :1961-1966
[19]   Enzymes of parasite thiol metabolism as drug targets [J].
Krauth-Siegel, RL ;
Coombs, GH .
PARASITOLOGY TODAY, 1999, 15 (10) :404-409
[20]   FLAVOPROTEIN STRUCTURE AND MECHANISM .5. TRYPANOTHIONE REDUCTASE AND LIPOAMIDE DEHYDROGENASE AS TARGETS FOR A STRUCTURE-BASED DRUG DESIGN [J].
KRAUTHSIEGEL, RL ;
SCHONECK, R .
FASEB JOURNAL, 1995, 9 (12) :1138-1146